6-硝基-1,3-苯并二氧代l-5-胺 | 64993-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 6-硝基-1,3-苯并二氧代l-5-胺
• 英文名称: 5-Amino-6-nitro-1,3-benzdioxol
• 英文别名: 4-amino-5-nitro-1,2-(methylenedioxy)benzene；6-nitrobenzo[d][1,3]dioxol-5-amine；4,5-Methylendioxy-2-nitroanilin；2-amino-4,5-methylenedioxy-1-nitrobenzene；6-nitro-benzo[1,3]dioxol-5-ylamine；5-amino-6-nitro-1,3-benzodioxole；5-amino-6-nitrobenzo-1,3-dioxole；5-amino-6-nitro-1,3-benzodioxol；6-nitro-1,3-benzodioxol-5-amine
• CAS: 64993-07-3
• 化学式: C₇H₆N₂O₄
• mdl: MFCD00184722
• 分子量: 182.136
• InChiKey: TXZJXBGDLONQGP-UHFFFAOYSA-N

物化性质

• 熔点：
  199 °C
• 沸点：
  370.7±42.0 °C(Predicted)
• 密度：
  1.587±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  90.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932999099
• 储存条件：
  室温、密封保存，并保持干燥。

反应信息

• 作为反应物：
  描述：

  6-硝基-1,3-苯并二氧代l-5-胺 在 镍 磷酸 、 氢气 、 砷酸、原砷酸 、 三乙胺 作用下， 以 乙二醇乙醚 、 乙醇 为溶剂， 100.0~110.0 ℃ 、310.27 kPa 条件下， 反应 1.5h， 生成 2-[4-(9-Methyl-[1,3]dioxolo[4,5-f]quinolin-5-ylamino)-hexyl]-isoindole-1,3-dione
  参考文献：
  名称：

  Antimalarials. 13. 5-Alkoxy analogs of 4-methylprimaquine

  摘要：

  A series of nuclear and side-chain analogues of 4-methylprimaquine incorporating an alkoxy group in the 5-position of the quinoline nucleus has been prepared. The compounds were tested for suppressive antimalarial activity against Plasmodium berghei in mice and for radical curative antimalarial activity against Plasmodium cynomolgi in the rhesus monkey. Although the toxicity problems characteristic of the 8-aminoquinolines were not overcome, several of the compounds, surprisingly, were highly effective as both blood and tissue schizonticidal agents.

  DOI：

  10.1021/jm00350a016
• 作为产物：
  描述：

  3,4-亚甲基二氧基乙酰苯胺 在 硝酸 、 sodium ethanolate 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 3.25h， 生成 6-硝基-1,3-苯并二氧代l-5-胺
  参考文献：
  名称：

  신규한 디플루오로아세트산 유도체 화합물 및 이를 포함한 조성물

  摘要：

  本发明涉及一种新型的二氟乙酸衍生物化合物及包含它的各种用途的组合物，所述二氟乙酸衍生物化合物可以作为激活PPARα、β或γ中任一种的激动剂，不仅可以发挥单一作用，还可以表现出双重或三重效应，因此可以更有效地预防、改善或治疗与PPARs相关的代谢性疾病，同时还表现出美白和减少皱纹的活性，具有抗炎和抗氧化效果，因此可以作为各种组合物中有用的成分。

  公开号：

  KR20200011270A

文献信息

• FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
  申请人：Cai Xiong

  公开号：US20080234314A1

  公开（公告）日：2008-09-25

  The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

  本发明涉及含有融合氨基吡啶核的HSP90抑制剂，可用作HSP90的抑制剂，以及它们在治疗HSP90相关疾病和紊乱，如癌症、自身免疫疾病或神经退行性疾病中的用途。
• Derivate des 1.3-BenzdioxoIs, 52 Darstellung und Reaktionen von 1.3-Dioxolo[4.5-b]phenazinen / Derivatives of 1,3-Benzdioxoles, 52 Preparation and Reactions of 1,3-Dioxolo[4,5-b]phenazines
  作者：Franz Dallacker、Alfred Wagner

  DOI：10.1515/znb-1984-0717

  日期：1984.7.1

  We describe the preparation of the 1,3-dioxolo[4,5-b]phenazines 4 a -p formed by ferric chloride oxidation of the corresponding 2,2′-diaminodiphenylamines. They are obtained by condensing the o-nitrohalogenbenzenes 1 a -g with o-nitroanilines 2 a-i and reduction of the resulting 2,2′-dinitrodiphenylamines 3 a -p with H₂/Pd.

  我们描述了通过对应的2,2'-二氨基二苯胺进行氯化铁氧化制备1,3-二氧杂环[4,5-b]苝啉4 a -p的过程。它们是通过将o-硝基卤代苯1 a -g与o-硝基苯胺2 a-i缩合得到相应的2,2'-二硝基二苯胺3 a -p，然后用H₂/Pd还原而得到的。
• Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
  申请人：——

  公开号：US20030236260A1

  公开（公告）日：2003-12-25

  Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

  治疗IL-6相关疾病的方法涉及EP4受体配体，包括EP4受体拮抗剂。用于确定试验化合物对PGE2诱导的全血细胞活化效果的测定。
• Imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04435406A1

  公开（公告）日：1984-03-06

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.
• EP4 receptor inhibitors to treat rheumatoid arthritis
  申请人：——

  公开号：US20020077329A1

  公开（公告）日：2002-06-20

  The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.

  该发明涉及一种治疗哺乳动物类风湿性关节炎的方法，包括给予一种抑制前列腺素EP4受体（EP4）活性的药物。还涉及一种识别在体内选择性抑制EP4活性的药物的方法。